Use of valganciclovir for prevention and treatment of cytomegalovirus disease

Clinical Infectious Diseases

Volumn 46, Issue 1, 2008, Pages 28-29

  Snydman, David R ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; GRAFT RECIPIENT; HEALTH PROGRAM; HEART TRANSPLANTATION; HUMAN; INFECTION PREVENTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NOTE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; DRUG COMBINATION; IMMUNE DEFICIENCY; IMMUNOLOGY; POSTOPERATIVE COMPLICATION; TRANSPLANTATION; VIROLOGY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION;

EID: 39349090459     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523589     Document Type: Note

References (6)

1. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811-5.
2. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79:85-90.
3. Len O, Gavalda J, Aguado JM, et al. Valganciclovir as preemptive therapy or treatment for cytomegalovirus disease in solid organ transplantation. Clin Infect Dis 2007; 45:20-7.
4. Valganciclovir. In: Physicians desk reference, 16th ed. Montvale, NJ: Thompson PDR, 2006: 2816-20.
5. Mattes IM, Hainsworth EG, Hassan-Walker AF, et al . Kinetics of cytomegalovirus load decreases in solid organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191:89-92.
6. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7:2106-13.